Selecta Biosciences, Inc. (NASDAQ:SELB) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, July 12th.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

SELB has been the topic of a number of other research reports. UBS AG reissued a “buy” rating and issued a $26.00 target price on shares of Selecta Biosciences in a research note on Thursday, March 30th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of Selecta Biosciences in a research note on Tuesday, March 28th. Canaccord Genuity set a $25.00 price target on shares of Selecta Biosciences and gave the stock a “buy” rating in a research note on Saturday, May 13th. Finally, ValuEngine raised shares of Selecta Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, June 30th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $26.00.

Selecta Biosciences (NASDAQ SELB) opened at 17.98 on Wednesday. The firm has a 50 day moving average of $18.17 and a 200 day moving average of $14.86. Selecta Biosciences has a 1-year low of $10.26 and a 1-year high of $28.00.

Selecta Biosciences (NASDAQ:SELB) last issued its earnings results on Thursday, May 11th. The company reported ($0.82) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.22) by $0.40. Selecta Biosciences had a negative net margin of 715.40% and a negative return on equity of 76.21%. The business had revenue of $0.14 million for the quarter. On average, equities research analysts forecast that Selecta Biosciences will post ($3.34) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/08/selecta-biosciences-inc-selb-upgraded-to-hold-at-zacks-investment-research-updated-updated-updated.html.

In related news, Director Timothy A. Springer acquired 16,104 shares of the firm’s stock in a transaction on Thursday, May 18th. The stock was bought at an average cost of $14.00 per share, with a total value of $225,456.00. Following the acquisition, the director now directly owns 11,244 shares in the company, valued at $157,416. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edwin M. Kania, Jr. sold 266,795 shares of the firm’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $14.00, for a total transaction of $3,735,130.00. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 355,413 shares of company stock worth $6,232,567 and have sold 321,819 shares worth $4,765,494.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Candriam Luxembourg S.C.A. acquired a new position in Selecta Biosciences during the first quarter valued at approximately $444,000. Hikari Power Ltd acquired a new position in Selecta Biosciences during the first quarter valued at approximately $349,000. Bank of New York Mellon Corp acquired a new position in Selecta Biosciences during the first quarter valued at approximately $211,000. UBS Group AG raised its position in Selecta Biosciences by 1,215.9% in the first quarter. UBS Group AG now owns 71,361 shares of the company’s stock valued at $1,022,000 after buying an additional 65,938 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Selecta Biosciences by 83.1% in the first quarter. Goldman Sachs Group Inc. now owns 31,588 shares of the company’s stock valued at $452,000 after buying an additional 14,332 shares during the period. 46.27% of the stock is owned by institutional investors and hedge funds.

About Selecta Biosciences

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.